ViiV Healthcare, a global specialist in HIV treatment, announced yesterday the submission of 13 abstracts from its portfolio of innovative licensed HIV prevention and treatment options. These include two-drug and two long-acting regimens. The presentation will take place at the annual meeting of the Infectious Diseases Society of America (IDSA), which will be held virtually from September 29 to October 3.

The ViiV Healthcare company is owned by GlaxoSmithKline, and its shareholders include Pfizer Inc. and Shionogi Limited, two leading companies in the healthcare industry.

Kimberly smith, the company’s head of research and development, stated: “The vast amount of data we are presenting at IDWeek 2021 demonstrates our commitment to understanding and addressing the range of evolving needs and challenges that people living with or living with HIV face.

Among the key summaries to be presented are: the findings at week 144 of the TANGO study evaluating the switch to the fixed-dose combination of Dovato (dolutegravir / lamivudine), compared to the continuation of tenofovir alafenamide (TAF).

The 48-week subgroup analyzes of the STAT study, which investigated the safety and efficacy of dolutegravir / lamivudine for the treatment of HIV-1. Also the results of pregnancy and birth after maternal use of dolutegravir (DTG).

Likewise, we will present the results that analyze the impact of COVID-19 on HIV treatment and care among participants in the BRIGHTE trial, and the findings of the retrospective study that examines the patterns of use among people receiving therapy based on tenofovir as pre-exposure prophylaxis (PrEP) in the United States.

Read:  The five years that changed Facebook (without actually changing anything)